Kaiser Permanente Creatinine Safety Program: A Mechanism to Ensure Widespread Detection and Care for Chronic Kidney Disease - 22/10/15
, Mark P. Rutkowski, MD b, David C. Selevan, BS b, Michael Batech, DrPH c, Royann Timmins, RN b, Jeff M. Slezak, MS c, Steven J. Jacobsen, MD, PhD c, Michael H. Kanter, MD bAbstract |
Background |
Chronic kidney disease is highly prevalent but is challenging to diagnose because of the need to establish chronicity. Within the current healthcare environment, a single abnormal creatinine measurement often can go without a follow-up, which can lead to missed diagnoses or diagnostic errors. The Kaiser Permanente Southern California creatinine safety program (the Creatinine SureNet) was created to help ensure that all single abnormal creatinine results had a follow-up evaluation.
Methods |
In the period February 1, 2010, to March 1, 2014, the electronic health records were used to capture individuals with single abnormal creatinine results that went >90 days without a repeat measurement. A coordinated effort among a centralized regional nurse and providers was used to communicate with patients and order a repeat creatinine measurement.
Results |
A total of 12,396 individuals were identified (84% ambulatory care encounters). A total of 6981 individuals (52%) followed up with a repeat measurement. Female patients, non-Hispanic whites, and older individuals were more likely to obtain a repeat measurement. Subsequently, 3668 individuals had chronic kidney disease confirmed. Within 6 months, 1550 patients had chart documentation of their chronic kidney disease and 336 patients had a nephrology consultation.
Conclusions |
The ambulatory care environment, given its high volume and various prioritizations, is an under-recognized area where diagnostic errors are not uncommon and failure to follow up on abnormal test results can occur routinely. The Kaiser Permanente Southern California Creatinine SureNet program leverages the electronic health records and its multidisciplinary resources in an effort to ensure that patients with potential chronic kidney disease are identified and managed properly.
Le texte complet de cet article est disponible en PDF.Keywords : Chronic kidney disease, Diagnostic errors, Health outcomes, Quality and safety program
Plan
| Funding: This study was funded and supported by the Regional Quality and Clinical Analysis Department and the Department of Research and Evaluations at Kaiser Permanente Southern California. |
|
| Conflict of Interest: None. |
|
| Authorship: All authors had access to the data and played a role in writing this manuscript. |
Vol 128 - N° 11
P. 1204 - novembre 2015 Retour au numéro
Article précédent
- Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks
- Sripal Bangalore, Gbenga Ogedegbe, Joyce Gyamfi, Yu Guo, Jason Roy, Keith Goldfeld, Christopher Torgersen, Louis Capponi, Christopher Phillips, Nirav R. Shah
- Quadriceps Strength as a Predictor of Mortality in Coronary Artery Disease
- Kentaro Kamiya, Takashi Masuda, Shinya Tanaka, Nobuaki Hamazaki, Yuya Matsue, Alessandro Mezzani, Ryota Matsuzawa, Kohei Nozaki, Emi Maekawa, Chiharu Noda, Minako Yamaoka-Tojo, Yasuo Arai, Atsuhiko Matsunaga, Tohru Izumi, Junya Ako
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?